4SC AG — Board/Management Information 2008

Jun 6, 2008

News Details

Corporate | 6 June 2008 09:00

4SC announces changes in Management and Supervisory Board

4SC AG / Change of Personnel

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Planegg-Martinsried, Germany, 06 June 2008 - The Martinsried-based drug
discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC)
today announced that Dr Gerhard Keilhauer will resign from the Management
Board of 4SC AG for personal reasons with effect from 1 July 2008. Dr
Keilhauer has been a member of the 4SC AG board since 2001. As Chief
Development Officer, he was primarily responsible for the implementation of
all advanced pre-clinical and clinical studies that are part of 4SC AG’s
development projects.

Dr Ulrich Dauer, Chief Executive Officer of 4SC AG, states: 'On behalf of
my colleagues of the Management Board I would like to thank Dr Keilhauer
for his contribution over the past years. With him, we had an expert on
board, who supported us substantially in setting up a sustainable and sound
project pipeline and in the fast development of advanced projects towards
clinical studies. One of his major achievements for our company is the
development of our first-class development team and the success of our
clinical substance SC12267.'

With effect from 1 July 2008, the Supervisory Board has appointed Dr Bernd
Hentsch as new Chief Development Officer. Dr Hentsch has extensive
experience in the fields of research and industry. As a former founding
member and board member of G2M Cancer Drugs AG, he until recently held the
position of Chief Development Officer at TopoTarget, a globally active,
biopharmaceutical company focused on cancer research, with world-leading
expertise in Histone deacetylase (HDAC) inhibitors.
Before that, Dr Hentsch worked in the fields of molecular immunology and
oncology. As Deputy Head of Preclinical Oncology at Merck KGaA, he was in
charge of pharmaceutical drug development.

'We are pleased to have such an industry expert joining us for the
continuation of our development projects,' declares Ulrich Dauer. 'Later
this year, at least two more projects from our pipeline might advance into
clinical development including, in all likelihood, a project in the field
of oncology.'

In addition, 4SC AG recently announced that several oncology projects were
taken over from Nycomed, including a clinical phase I project. 'We are
confident that Dr Hentsch, with his extensive expertise in monitoring
clinical trials of potential substances for the treatment of cancer, will
be a great support for us in developing our future pipeline projects,'
Dauer continues.

The company also announced the appointment to the Supervisory Board of Dr
Thomas Strüngmann and Helmut Jeggle, both representatives of Santo Holding
(Deutschland) GmbH, at yesterday's Annual General Shareholders’ Meeting. At
the same time, Dr Robert B. O'Connell and Dr Brian Morgan have retired from
the Supervisory Board, at their own request.

In addition, all other agenda items up for approval were passed by the
Annual General Shareholders’ Meeting by the required majorities.

About 4SC:
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 74, the company develops novel drug candidates for
inflammatory diseases, cancer and infectious diseases using a
cheminformatics based technology platform. Traditional high throughput
screening of therapeutic agents has been transferred from the lab to the
computer. Thus, the company offers substantial cost and time advantages as
well as increased success rates in drug development. 4SC AG utilises its
technology platform, which is protected by patent, to create a sustainable
project pipeline of active agents to be developed up to the early clinical
phases ('proof of concept') and subsequently licensed to the pharmaceutical
industry in return for advance and milestone payments as well as royalties.
There are currently six projects in the pipeline and a so-called ideas’
pool with further development candidates. The first project for the
treatment of rheumatoid arthritis has already successfully completed
clinical phase IIa. Four other product candidates are in pre-clinical
development and another project is in the research stage. In addition, the
company is implementing its technology platform in partnerships with
pharmaceutical and biotechnology companies, and is already generating
initial revenues.

Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

Bettina von Klitzing
Manager Investor Relations & Public Relations
4SC AG
Tel.: +49 (0) 89 70 07 63 – 0
bettina.von.klitzing@4sc.com

06.06.2008 Financial News transmitted by DGAP

Language: English
Issuer: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---